Personalized Retinal Disease Treatment Platform

A wearable ocular device with a MEMS-based delivery mechanism and integrated sensor for real-time retinal health monitoring, enabling personalized treatment of retinal diseases through a cloud-based data analytics module.

The original patent disclosed compositions and methods for the inhibition of diabetic retinopathy and retinal vein occlusion using cell permeant therapeutics. However, these methods rely on manual administration of eye drops, which can be inconvenient and may lead to inconsistent treatment outcomes. The new inventive concept addresses these limitations by introducing a wearable ocular device that provides controlled and sustained delivery of therapeutics, while also monitoring retinal health in real-time.

The wearable ocular device comprises a reservoir containing a cell permeant therapeutic, a MEMS-based delivery mechanism, and a sensor that monitors the patient's retinal health. The device can be programmed to deliver the therapeutic at predetermined intervals based on the patient's retinal health data, which is transmitted to a cloud-based data analytics module. The module provides personalized treatment recommendations to the patient, ensuring optimal treatment outcomes. The system enables real-time monitoring and adaptation to changing retinal health conditions, thereby improving treatment efficacy and patient quality of life.

The new claims introduce a paradigm shift in retinal disease treatment by integrating wearable technology, MEMS-based delivery, and cloud-based data analytics. The inventive concept's novelty lies in its ability to provide personalized, real-time treatment adaptation, which is not possible with manual eye drop administration.

Alternative embodiments may include varying the type of sensor used, incorporating additional features such as artificial intelligence-powered predictive analytics, or using different materials for the wearable ocular device. Variations may also include adapting the system for treatment of other ocular diseases or integrating with existing medical devices.

The personalized retinal disease treatment platform has significant commercial potential in the ophthalmology and healthcare industries, with potential applications in diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration treatment. The market for such a platform is substantial, with an estimated global value of over $10 billion by 2025.